Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20724739 | 0.87 | MAPK1 (0.48) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL19807165 | 0.87 | MAPK1 (0.48) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL19798448 | 0.82 | ALDH1A1 (0.43) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL19798465 | 0.78 | ALDH1A1 (0.55) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL19798441 | 0.76 | EPHX2 (0.49) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL19798442 | 0.75 | SMN1; SMN2 (0.44) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL19808245 | 0.74 | P2RX7 (0.53) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL12640167 | 0.74 | ALDH1A1 (0.82) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL12672465 | 0.74 | ALDH1A1 (0.82) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL19808494 | 0.73 | SMN1; SMN2 (0.43) | MAPK1ALDH1A1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | MAPK1 2736/4885ALDH1A1 2128/4885SMN1; SMN2 3655/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | MAPK1 2736/4885ALDH1A1 2128/4885SMN1; SMN2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.